Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Estrogen Receptor and the Gender Bias in Raynaud’s Phenomenon

Author(s): Manal Fardoun, Firas Kobeissy and Ali H. Eid*

Volume 31, Issue 2, 2024

Published on: 21 March, 2023

Page: [133 - 137] Pages: 5

DOI: 10.2174/0929867330666230220123237

Open Access Journals Promotions 2
conference banner
« Previous Next »
[1]
Charkoudian, N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol., 2010, 109(4), 1221-1228.
[2]
Vanhoutte, P.M. Handbook of Physiology; Bohr, D.F., Ed.; The American Physiological Society: Washington, D.C., 1980, Section 2: Circulation: Volume II: Vascular Smooth Muscle, pp. 443-474.
[3]
Wigley, F.M.; Flavahan, N.A. Raynaud’s phenomenon. N. Engl. J. Med., 2016, 375(6), 556-565.
[http://dx.doi.org/10.1056/NEJMra1507638] [PMID: 27509103]
[4]
Herrick, A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol., 2012, 8(8), 469-479.
[http://dx.doi.org/10.1038/nrrheum.2012.96] [PMID: 22782008]
[5]
Fardoun, M.M.; Nassif, J.; Issa, K.; Baydoun, E.; Eid, A.H. Raynaud’s phenomenon: A brief review of the underlying mechanisms. Front. Pharmacol., 2016, 7, 438.
[http://dx.doi.org/10.3389/fphar.2016.00438] [PMID: 27899893]
[6]
Block, J.A.; Sequeira, W. Raynaud’s phenomenon. Lancet, 2001, 357(9273), 2042-2048.
[http://dx.doi.org/10.1016/S0140-6736(00)05118-7] [PMID: 11438158]
[7]
Roustit, M.; Khouri, C.; Blaise, S.; Villier, C.; Carpentier, P.; Cracowski, J.L. Pharmacology of Raynaud’s phenomenon. Therapie, 2014, 69(2), 115-128.
[http://dx.doi.org/10.2515/therapie/2013068] [PMID: 24926630]
[8]
Prete, M.; Fatone, M.C.; Favoino, E.; Perosa, F. Raynaud’s phenomenon: From molecular pathogenesis to therapy. Autoimmun. Rev., 2014, 13(6), 655-667.
[http://dx.doi.org/10.1016/j.autrev.2013.12.001] [PMID: 24418302]
[9]
Maverakis, E.; Patel, F.; Kronenberg, D.G.; Chung, L.; Fiorentino, D.; Allanore, Y.; Guiducci, S.; Hesselstrand, R.; Hummers, L.K.; Duong, C.; Kahaleh, B.; Macgregor, A.; Matucci-Cerinic, M.; Wollheim, F.A.; Mayes, M.D.; Gershwin, M.E. International consensus criteria for the diagnosis of Raynaud’s phenomenon. J. Autoimmun., 2014, 48-49, 60-65.
[http://dx.doi.org/10.1016/j.jaut.2014.01.020] [PMID: 24491823]
[10]
Wigley, F.M. Raynaud’s phenomenon. N. Engl. J. Med., 2002, 347(13), 1001-1008.
[http://dx.doi.org/10.1056/NEJMcp013013] [PMID: 12324557]
[11]
Easter, M.J.; Marshall, J.M. Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud’s disease. Clin. Sci., 2005, 109(1), 45-54.
[http://dx.doi.org/10.1042/CS20040262] [PMID: 15769250]
[12]
McCance, K.L.; Huether, S.E. Pathophysiology: The Biologic Basis for Disease in Adults and Children; Elsevier: Amsterdam, 2013.
[13]
Freedman, R.R.; Sabharwal, S.C.; Moten, M.; Migály, P. Local temperature modulates alpha 1- and alpha 2-adrenergic vasoconstriction in men. Am. J. Physiol., 1992, 263(4 Pt 2), H1197-H1200.
[PMID: 1329562]
[14]
Polónia, J.J.; Paiva, M.Q.; Guimarāes, S. Pharmacological characterization of postsynaptic α-adrenoceptor subtypes in five different dog arteries in-vitro. J. Pharm. Pharmacol., 2011, 37(3), 205-208.
[http://dx.doi.org/10.1111/j.2042-7158.1985.tb05043.x] [PMID: 2858570]
[15]
Freedman, R.R.; Moten, M.; Migály, P.; Mayes, M. Cold-induced potentiation of α2-adrenergic vasoconstriction in primary Raynaud’s disease. Arthritis Rheum., 1993, 36(5), 685-690.
[http://dx.doi.org/10.1002/art.1780360517] [PMID: 8387786]
[16]
Eid, A.H.; Chotani, M.A.; Mitra, S.; Miller, T.J.; Flavahan, N.A. Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle α 2C -adrenoceptors. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(1), H266-H272.
[http://dx.doi.org/10.1152/ajpheart.00084.2008] [PMID: 18487435]
[17]
Bailey, S.R.; Eid, A.H.; Mitra, S.; Flavahan, S.; Flavahan, N.A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ. Res., 2004, 94(10), 1367-1374.
[http://dx.doi.org/10.1161/01.RES.0000128407.45014.58] [PMID: 15087420]
[18]
Jeyaraj, S.C.; Chotani, M.A.; Mitra, S.; Gregg, H.E.; Flavahan, N.A.; Morrison, K.J. Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol., 2001, 60(6), 1195-1200.
[http://dx.doi.org/10.1124/mol.60.6.1195] [PMID: 11723226]
[19]
Garner, R.; Kumari, R.; Lanyon, P.; Doherty, M.; Zhang, W. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open, 2015, 5(3), e006389.
[http://dx.doi.org/10.1136/bmjopen-2014-006389] [PMID: 25776043]
[20]
Mustafa, M.; Alsulaimani, H.; Alhaddad, A.; Almujil, S.; Albar, Z.; Bawazir, Y.; Alsolaimani, R.; Omair, M.A. Prevalence of Raynaud’s phenomenon in Saudi Arabia. Open Access Rheumatol., 2022, 14, 17-24.
[http://dx.doi.org/10.2147/OARRR.S352655] [PMID: 35299881]
[21]
Voulgari, P.V.; Alamanos, Y.; Papazisi, D.; Christou, K.; Papanikolaou, C.; Drosos, A.A. Prevalence of Raynaud’s phenomenon in a healthy Greek population. Ann. Rheum. Dis., 2000, 59(3), 206-210.
[http://dx.doi.org/10.1136/ard.59.3.206] [PMID: 10700429]
[22]
Wehbe, Z.; Nasser, S.A.; El-Yazbi, A.; Nasreddine, S.; Eid, A.H. Estrogen and bisphenol A in hypertension. Curr. Hypertens. Rep., 2020, 22(3), 23.
[http://dx.doi.org/10.1007/s11906-020-1022-z] [PMID: 32114652]
[23]
Fardoun, M.; Dehaini, H.; Shaito, A.; Mesmar, J.; El-Yazbi, A.; Badran, A.; Beydoun, E.; Eid, A.H. The hypertensive potential of estrogen: An untold story. Vascul. Pharmacol., 2020, 124, 106600.
[http://dx.doi.org/10.1016/j.vph.2019.106600] [PMID: 31629918]
[24]
Dehaini, H.; Fardoun, M.; Abou-Saleh, H.; El-Yazbi, A.; Eid, A.A.; Eid, A.H. Estrogen in vascular smooth muscle cells: A friend or a foe? Vascul. Pharmacol., 2018, 111, 15-21.
[http://dx.doi.org/10.1016/j.vph.2018.09.001] [PMID: 30227233]
[25]
Eid, A.H.; Maiti, K.; Mitra, S.; Chotani, M.A.; Flavahan, S.; Bailey, S.R.; Thompson-Torgerson, C.S.; Flavahan, N.A. Estrogen increases smooth muscle expression of α 2C -adrenoceptors and cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(3), H1955-H1961.
[http://dx.doi.org/10.1152/ajpheart.00306.2007] [PMID: 17644575]
[26]
Greenstein, D.; Jeffcote, N.; Ilsley, D.; Kester, R.C. The menstrual cycle and Raynaud’s phenomenon. Angiology, 1996, 47(5), 427-436.
[http://dx.doi.org/10.1177/000331979604700501] [PMID: 8644939]
[27]
Mayes, M.D. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ. Health Perspect., 1999, 107(Suppl. 5), 743-748.
[http://dx.doi.org/10.1289/ehp.99107s5743] [PMID: 10502540]
[28]
Fraenkel, L.; Zhang, Y.; Chaisson, C.E.; Evans, S.R.; Wilson, P.W.; Felson, D.T. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann. Intern. Med., 1998, 129(3), 208-211.
[http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00009] [PMID: 9696729]
[29]
Chan, N.N.; MacAllister, R.J.; Colhoun, H.M.; Vallance, P.; Hingorani, A.D. Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J. Clin. Endocrinol. Metab., 2001, 86(6), 2499-2504.
[PMID: 11397846]
[30]
Li, T.; Xiao, X.; Zhang, J.; Zhu, Y.; Hu, Y.; Zang, J.; Lu, K.; Yang, T.; Ge, H.; Peng, X.; Lan, D.; Liu, L. Age and sex differences in vascular responsiveness in healthy and trauma patients: contribution of estrogen receptor-mediated Rho kinase and PKC pathways. Am. J. Physiol. Heart Circ. Physiol., 2014, 306(8), H1105-H1115.
[http://dx.doi.org/10.1152/ajpheart.00645.2013] [PMID: 24531808]
[31]
Charkoudian, N.; Stachenfeld, N. Sex hormone effects on autonomic mechanisms of thermoregulation in humans. Auton. Neurosci., 2016, 196, 75-80.
[http://dx.doi.org/10.1016/j.autneu.2015.11.004] [PMID: 26674572]
[32]
Fardoun, M.M.; Issa, K.; Maaliki, D.; Nasser, S.A.; Baydoun, E.; Eid, A.H. Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction. Vascul. Pharmacol., 2020, 131, 106690.
[http://dx.doi.org/10.1016/j.vph.2020.106690] [PMID: 32407896]
[33]
McNeill, A.M.C.; Leslie, F.M.; Krause, D.N.; Duckles, S.P. Gender difference in levels of α2-adrenoceptor mRNA in the rat tail artery. Eur. J. Pharmacol., 1999, 366(2-3), 233-236.
[http://dx.doi.org/10.1016/S0014-2999(98)00948-0] [PMID: 10082204]
[34]
Serizawa, I.; Iwasaki, N.; Ishida, H.; Saito, S.; Ishikawa, T. G-protein coupled estrogen receptor-mediated non-genomic facilitatory effect of estrogen on cooling-induced reduction of skin blood flow in mice. Eur. J. Pharmacol., 2017, 797, 26-31.
[http://dx.doi.org/10.1016/j.ejphar.2017.01.013] [PMID: 28089920]
[35]
Fardoun, M.; Mondello, S.; Kobeissy, F.; Eid, A.H. G protein estrogen receptor as a potential therapeutic target in Raynaud’s phenomenon. Front. Pharmacol., 2022, 13, 1061374.
[http://dx.doi.org/10.3389/fphar.2022.1061374] [PMID: 36438809]
[36]
Shaito, A.; Aramouni, K.; Assaf, R.; Parenti, A.; Orekhov, A.; Yazbi, A.E.; Pintus, G.; Eid, A.H. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. Front. Biosci.-Landmark, 2022, 27(3), 0105.
[http://dx.doi.org/10.31083/j.fbl2703105] [PMID: 35345337]
[37]
Ismail, H.; Shakkour, Z.; Tabet, M.; Abdelhady, S.; Kobaisi, A.; Abedi, R.; Nasrallah, L.; Pintus, G.; Al-Dhaheri, Y.; Mondello, S.; El-Khoury, R.; Eid, A.H.; Kobeissy, F.; Salameh, J. Traumatic brain injury: Oxidative stress and novel anti-oxidants such as mitoquinone and edaravone. Antioxidants, 2020, 9(10), 943.
[http://dx.doi.org/10.3390/antiox9100943] [PMID: 33019512]
[38]
Thuan, D.T.B.; Zayed, H.; Eid, A.H.; Abou-Saleh, H.; Nasrallah, G.K.; Mangoni, A.A.; Pintus, G. A potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic sclerosis. Front. Immunol., 2018, 9, 1985.
[http://dx.doi.org/10.3389/fimmu.2018.01985] [PMID: 30283435]
[39]
Hamze, K.; Abdallah, R.H.; Younis, N.K.; Fardoun, M.; Darwiche, N.; Kobeissy, F.; Iratni, R.; Bouhadir, K.; Eid, A.H. 2-nucleobase-substituted 4,6-diaminotriazine analogs: Synthesis and anti-cancer activity in 5-fluorouracil-sensitive and resistant colorectal cancer cells. Curr. Med. Chem., 2022.
[PMID: 36111761]
[40]
AlKahlout, A.; Fardoun, M.; Mesmar, J.; Abdallah, R.; Badran, A.; Nasser, S.A.; Baydoun, S.; Kobeissy, F.; Shaito, A.; Iratni, R.; Muhammad, K.; Baydoun, E.; Eid, A.H. Origanum syriacum L. attenuates the malignant phenotype of MDA-MB231 breast cancer cells. Front. Oncol., 2022, 12, 922196.
[http://dx.doi.org/10.3389/fonc.2022.922196] [PMID: 35847867]
[41]
Al Attar, A.A.; Fahed, G.I.; Hoballah, M.M.; Pedersen, S.; El-Yazbi, A.F.; Nasser, S.A.; Bitto, A.; Orekhov, A.N.; Eid, A.H. Mechanisms underlying the effects of caloric restriction on hypertension. Biochem. Pharmacol., 2022, 200, 115035.
[http://dx.doi.org/10.1016/j.bcp.2022.115035] [PMID: 35427570]
[42]
Slika, H.; Mansour, H.; Wehbe, N.; Nasser, S.A.; Iratni, R.; Nasrallah, G.; Shaito, A.; Ghaddar, T.; Kobeissy, F.; Eid, A.H. Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms. Biomed. Pharmacother., 2022, 146, 112442.
[http://dx.doi.org/10.1016/j.biopha.2021.112442] [PMID: 35062053]
[43]
Mesmar, J.; Fardoun, M.M.; Abdallah, R.; Al Dhaheri, Y.; Yassine, H.M.; Iratni, R.; Badran, A.; Eid, A.H.; Baydoun, E. Ziziphus nummularia attenuates the malignant phenotype of human pancreatic cancer cells: Role of ROS. Molecules, 2021, 26(14), 4295.
[http://dx.doi.org/10.3390/molecules26144295] [PMID: 34299570]
[44]
Fardoun, M.; Al-Shehabi, T.; El-Yazbi, A.; Issa, K.; Zouein, F.; Maaliki, D.; Iratni, R.; Eid, A.H. Ziziphus nummularia inhibits inflammation-induced atherogenic phenotype of human aortic smooth muscle cells. Oxid. Med. Cell. Longev., 2017, 2017, 1-10.
[http://dx.doi.org/10.1155/2017/4134093] [PMID: 28593025]
[45]
White, R.E.; Gerrity, R.; Barman, S.A.; Han, G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids, 2010, 75(11), 788-793.
[http://dx.doi.org/10.1016/j.steroids.2009.12.007] [PMID: 20060403]
[46]
Landry, G.J. Current medical and surgical management of Raynaud’s syndrome. J. Vasc. Surg., 2013, 57(6), 1710-1716.
[http://dx.doi.org/10.1016/j.jvs.2013.03.012] [PMID: 23618525]
[47]
El-Hachem, N.; Fardoun, M.M.; Slika, H.; Baydoun, E.; Eid, A.H. Repurposing cilostazol for Raynaud’s phenomenon. Curr. Med. Chem., 2021, 28(12), 2409-2417.
[http://dx.doi.org/10.2174/0929867327666200903114154] [PMID: 32881655]

Rights & Permissions Print Cite
Article Metrics
25
4
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy